Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694667 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorders and Hyperactivity, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 1
- Study location
NCT01694667: Completed Phase 2 study of Autism Spectrum Disorders and Hyperactivity, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
NCT01694667 is a Phase 2 study of Autism Spectrum Disorders and Hyperactivity that has completed, run by Hugo W. Moser Research Institute at Kennedy Krieger. The registered enrollment target is 57 participants, below the 165-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01694667, a Phase 2 study of Autism Spectrum Disorders and Hyperactivity, has completed, sponsored by Hugo W. Moser Research Institute at Kennedy Krieger.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is an internet-based, randomized, double-blind, placebo-controlled trial which will assess changes in hyperactivity in children ages five through eight with an autism spectrum disorders (ASD) and elevated levels of hyperactivity. In order to answer this question, this study will assess changes in hyperactivity as measured by the Aberrant Behavior Checklist (ABC) in children with ASD and elevated baseline levels of hyperactivity who are randomly assigned to use 1.3 grams of omega-3 fatty acids daily compared to placebo. The overwhelming majority of study procedures, including recruitment, informed consent, assessment of inclusion and exclusion criteria, and collection of baseline and outcome measures will take place over the internet.
Primary Outcome
The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The hyperactivity subscale is comprised of 16 items. The outcome measure is the change from baseline to 6 weeks. The total score ranges from 0 to 48.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Omega-3 Fatty Acids
Study Locations (1)
Maryland
- This study is open to continental USA - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT01694667 record still lists
NCT01694667 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 165-participant average among 20 other Autism Spectrum Disorders trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Autism Spectrum Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01694667 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01694667 about?
NCT01694667 is a clinical study titled "Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder". The proposed study is an internet-based, randomized, double-blind, placebo-controlled trial which will assess changes in hyperactivity in children ages five through eight with an autism spectrum disorders (ASD) and elevated levels of hyperactivity. In order to answer this question, this study will a...
What is the current status of trial NCT01694667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2012-09. Estimated completion is 2013-05.
What conditions does trial NCT01694667 study?
This clinical trial studies the following conditions: Autism Spectrum Disorders, Hyperactivity.
What interventions are being tested in trial NCT01694667?
The interventions under investigation include: Placebo (OTHER), Omega-3 Fatty Acids (DRUG).
Who is sponsoring clinical trial NCT01694667?
This trial is sponsored by Hugo W. Moser Research Institute at Kennedy Krieger, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01694667 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01694667's enrollment target sits among peer trials
57 10th of 20 higher than 11 of 20 other Autism Spectrum Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Role of Vasopressin in the Social Deficits of Autism
COMPLETED · Phase 2
-
Acamprosate in Youth With Fragile X Syndrome
COMPLETED · Phase 2
-
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
COMPLETED · Phase 2
-
Water Competency Intervention in Autism
RECRUITING · NA
-
Phenotypic and Genetic Factors in Autism Spectrum Disorders
ACTIVE NOT RECRUITING
-
Project AFECT (Autism Family Empowerment Coaching and Training Program)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia